Allegrezza et al. indicated that trametinib, a MEK inhibitor, induces anti-tumor T-cell activation by inhibiting tumor-derived OPN-mediated MDSC recruitment in breast cancer [150]. Here, SPP1 is linked to breast carcinoma.